A Randomized Open-Label, Multi-Center Pivotal Study of ANG1005 Compared with Physicians Best Choice in HER2-Negative Breast Cancer Patients with Newly Diagnosed Leptomeningeal Carcinomatosis and Previously Treated Brain Metastases (ANGLeD)
ANG1005 in Leptomeningeal Disease From Breast Cancer (ANGLeD)
Sponsor: Angiochem Inc
Enrolling: Male and Female Patients
IRB Number: AAAS1589
U.S. Govt. ID: NCT03613181
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This research study compares the effects (good and/or bad), of the study drug (ANG1005) with standard treatments currently available for leptomeningeal metastases to find out which is better. In this study, you will get either ANG1005 or standard treatment available for leptomeningeal metastases. You will not get both.
This study is closed
Aya Haggiagi, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Do you have at least 2 months of expected survival? Yes No
Do you have HER2-negative breast cancer? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator